4.5 Article

The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity

Journal

MEDICAL MICROBIOLOGY AND IMMUNOLOGY
Volume 212, Issue 3, Pages 203-220

Publisher

SPRINGER
DOI: 10.1007/s00430-023-00763-y

Keywords

COVID-19; Symptomatic; Asymptomatic; IgG avidity

Ask authors/readers for more resources

Assessing the avidity of IgG antibodies against SARS-CoV-2 in COVID-19 patients and carriers is crucial for understanding the protective/damaging aspects of immunity. This study found that symptomatic patients had lower antibody avidities compared to asymptomatic individuals, despite higher IgG levels. One-dose and two-dose vaccination increased anti-S antibody avidity in both groups, with significant differences detected in the symptomatic group. However, vaccination did not significantly affect anti-N avidity. The findings suggest the importance of antibody avidity measurement in predicting effective immunity and prognosis for SARS-CoV-2 infection.
Gaining more appreciation on the protective/damaging aspects of anti-SARS-CoV-2 immunity associated with disease severity is of great importance. This study aimed to evaluate the avidity of serum IgG antibodies against SARS-CoV-2 spike (S) and nucleocapsid (N) in hospitalized symptomatic COVID-19 patients and asymptomatic RT-PCR-confirmed SARS-CoV-2 carriers as well as to compare antibody avidities with respect to vaccination status, vaccination dose and reinfection status. Serum levels of anti-S and anti-N IgG were determined using specific ELISA kits. Antibody avidity was determined by urea dissociation assay and expressed as avidity index (AI) value. Despite higher IgG levels in the symptomatic group, AI values of both anti-S and anti-N IgG were significantly lower in this group compared to asymptomatic individuals. In both groups, anti-S AI values were elevated in one-dose and two-dose vaccinees versus unvaccinated subjects, although significant differences were only detected in the symptomatic group. However, anti-N avidity showed no significant difference between the vaccinated and unvaccinated subgroups. Almost all vaccinated patients of different subgroups (based on vaccine type) had higher anti-S IgG avidity, while the statistical significance was detected only between those receiving Sinopharm compared to the unvaccinated subgroup. Also, statistically significant differences in antibody AIs were only found between primarily infected individuals of the two groups. Our findings indicate a key role for anti-SARS-CoV-2 IgG avidity in protection from symptomatic COVID-19 and calls for the incorporation of antibody avidity measurement into the current diagnostic tests to predict effective immunity toward SARS-CoV-2 infection or even for prognostic purposes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available